There are approximately 54 000 nurse and midwife prescribers across the United Kingdom (UK), with 19 000 nurse independent and supplementary prescribers. Prostate cancer specialist nurses are ideally suited to implement advanced levels of practice in non-medical prescribing, but little has been detailed in the literature about the prescribing practice in this clinical context. This paper set out to critically review evidence-based recommendations for Prostate Cancer Specialist Nurses using a case study reflection to contextualize the role of non-medical prescribing. A structured literature review was conducted in a range of electronic databases (DARE, Cochrane, MEDLINE, BNI, PsychINFO, EMBASE and CIHAHL), and a grey literature search in google, to identify studies employing a qualitative and/or quantitative methods. National (UK) and European clinical guidelines and legislative frameworks were also included. Methodological evaluation was conducted and evidence-based recommendations were integrated into a narrative synthesis. A multidisciplinary and proactive approach to the management of men with metastatic prostate cancer ensures safe and effective prescribing practice, and optimizes supportive care delivery. A reflective case study has illuminated the key features necessary to maximize the success of non-medical prescribing in prostate cancer care and captures the importance of good working relationships. While different practice models will emerge, the Prostate Cancer Model of Consultation may facilitate a structured framework for safe practice, embedded in effective communication strategies. Non-medical prescribers must be committed to continual professional development, and prescribe safely within individual competencies and scope of professional practice. There is a pressing need for further research to evaluate prescribing practices with a particular focus on the nature of influencing factors on prescribing decisions, cost-effectiveness and a more detailed understanding of how team working and inter-team referral affects prescribing decisions between the Multidisciplinary Team (MDT) members.
INTRODUCTION
Following the publication of the Crown report in 1999 (Department of Health, 1999) , several legislative changes have taken place to implement the Government's policy (Department of Health, 2007; Department of Health, 2006; The Scottish Government, 2006;  Service (NHS) (Van Ruth et al., 2008) . Inevitably, prescribing practice differs across international countries, but there are common aspects to prescribing practice that include supplementary and independent prescribing. Supplementary prescribing has been described as a voluntary partnership between an independent prescriber (such as a doctor) and a supplementary prescriber (other allied healthcare professionals) to implement an agreed patient-specific clinical management plan with the patient's consent (Watterson et al., 2009) . Whereas, independent prescribing is defined as a healthcare professional who is responsible and accountable for the assessment of patients with undiagnosed conditions and for the evidence-based decisions about the clinical management and prescribing (The Scottish Government, 2006) .
A recent systematic review aimed to evaluate the effectiveness of nurse prescribing in comparison to physician prescribing (Gielen et al., 2014) . The conclusions drawn from their review suggested that patients were either, generally more or equally satisfied with the care provided by nurses when compared to the traditional care provided by Doctors. The conclusion from this study indicate that nurses prescribe for a wide range of patients in difference clinical contexts, yet still in comparable ways to Doctors. However, there are a number of limitations in their systematic review worthy of comment. Some of the included studies had small sample sizes, and there were few Randomized Control Trials (RCTs), as such the conclusions drawn from this review are considered tentative because further high quality rigorous RCT's are needed to evaluate the effectiveness of nurse prescribing, in a range of clinical contexts. Undoubtedly, other factors can influence patient reports of satisfaction of nurse prescribing, and a further limitation was that of variation in the 'satisfaction instruments' used across the included studies. Very rarely nurse prescribing is performed in isolation from other nursing tasks. Prescribing practice is fully embedded in other activities that might include taking a clinical history, formulating a diagnosis and communication skills. Thus, bias is possible in the satisfaction ratings across the included studies, for example, it might be patients' satisfaction rating of the consultation skills and not solely prescribing activities per se. Moreover, little is known in the reported literature about the cost efficiency of non-medical prescribing in a variety of specialist nursing contexts compared to Doctors (Hollinghurst et al., 2006) .
Despite these limitations, it is an emerging evidence base to support non-medical prescribing in nursing and with the increasing pressure on NHS resources, nurses are in a unique position to develop advanced roles to help meet increasing demands (Department of Health, 2010; Department of Health, 2008) , in particular for cancer services (Department of Health, 2013) . Specialist nurses are already providing follow-up clinics for patients with prostate cancer as part of the multidisciplinary approach recommended in national clinical guidelines (NICE, 2014) and patient feedback has illustrated acceptance and positive attitudes towards nurse-led prostate cancer clinics (Wade et al., 2015) . We argue, that prostate cancer specialist nurses are ideally suited to implement advanced levels of practice in non-medical prescribing, but recognize little has been detailed in the literature about the prescribing practice, specifically, for prostate cancer specialist nurses, and further service evaluation and research is needed (Paterson et al., 2015b) . Therefore, the aim of this paper set out to critically review the evidence-based recommendations for prostate cancer nurses using a case study reflection to contextualize the role of non-medical prescribing, see Table 1 . To address the overall aim, we implemented the following objectives:
• Apply a model of consultation and relevant assessment tools within this case study.
• Critically evaluate the contemporary pharmacological knowledge base underpinning prescribing within legislative frameworks.
• Critically appraise current issues and non-medical factors impacting upon and influencing prescribing practice in the context of this case study.
• Reflect and critically evaluate prostate cancer specialist nurse's contribution to the multidisciplinary team within a framework of professional accountability and responsibility in relation to prescribing.
CONSULTATION AND ASSESSMENT TOOLS IN RELATION TO PRESCRIBING
The Department of Health has defined a non-medical prescriber as a practitioner (e.g. nurse, doctor, pharmacist, dentist) responsible and accountable for the assessment of patients with undiagnosed/diagnosed conditions and for decisions about the clinical management required (Scottish Government, 2006) . Therefore, central to safe and effective prescribing practice, non-medical prescribers may need to formulate a differential diagnosis and develop robust evidence-based clinical management plans during clinical consultations. A clinical consultation is a two-way process of information exchange between a healthcare professional and a patient. As such, a consultation may be initiated by the healthcare professional to provide health promotional intervention, or by the patient when they are unwell (Denness, 2015) . There are various approaches to consultation, and over recent decades there has been an evolution of various consultation models in the reported literature, but for the most part consultation models have been developed for General Practitioners up until now (Denness, 2015) , and not specifically for specialist nursing roles in cancer care. This poses the question about the suitability of existing models in the clinical context of prostate cancer care. A recent systematic review critically appraised existing models of consultation to date (Paterson and Nabi, 2016) , and concluded that none of the reviewed models in the available literature are suitable for use in prostate cancer for the following reasons: (i) no recognition of the cancer care continuum and its influence on consultations, (ii) lack of supported self-management recognizing cancer as a long-term condition, (iii) no appreciation of the complex factors that influence consultation for each individual man affected by prostate cancer (demographic, self-efficacy, cultural, etc.) and (iv) very little acknowledgement of the evidence base to inform management plans within the consultation itself.Therefore, a new model of consultation (Paterson and Nabi, 2016) was informed from appraisal of the empirical literature, and expert guidance from men affected by prostate cancer and members of the MDT, see Figure 1 .
REFLECTIONS ON THE CASE STUDY
A 75-year-old male presented to the Prostate Assessment Clinic and the Senior Prostate Cancer Specialist Nurse introduced herself, checked his date of birth against his case notes. The consultation was guided using the Prostate Cancer Model of Consultation. To develop 'partnership' the specialist nurse starts to build a relationship with him embedded in a person-centred communication (Stenner et al., 2011; Tay et al., 2011) . At the 'Information' gathering stage of the consultation the nurse sought clarification from him using open questioning to establish his understanding of why he has come for further prostate assessment (Tay et al., 2011) . This ensured he had time to elicit his 'ideas, concerns and expectations' from his perspective to promote partnership and person-centred care (Scottish Government, 2014; Matthys et al., 2009; Scottish Government, 2007) . His understanding was that his PSA was high, he had some pain and needed to have some further investigations. The Specialist Nurse explained her role within the prostate assessment clinic and gained informed consent to take a detailed systematic history and physical examination (Douglas et al., 2009) . The medical history was a structured assessment using open and closed questions to enable a comprehensive picture of the patient's health and health problems (Gask and Usherwood, 2002) . It included an in-depth medical history, psycho-social and medical (including any over the counter medications, complementary medications, recreational drugs and prescribed medications), current and previous medical treatments, the patient's health in general/performance status, risk and lifestyle factors and family history of prostate cancer (Bickley, 2013) .
In keeping with evidence-based recommendations the physical examination was explained and verbal consent provided which included a full assessment of lower urinary tract symptoms and the following tests: uroflometry, post-void bladder scan and urinalysis (Heidenreich et al., 2014b) . The results of investigations revealed a maximum flow rate of 20 mL per second, voided volume 237 mL, 17 mL post-void residual, and urinalysis was negative. The patient was asked to complete a standardized patient reported outcome measure, the International Prostate Symptom Score (IPSS), a standard questionnaire for the systematic assessment of lower urinary tract symptoms from the patient's perspective (Barry et al., 1992) . The IPSS has demonstrated reliability and validity (Lujan Galan et al., 1997) . Each question is rated on a scale of 0-5, with the total score range 0 to 35 (asymptomatic to very symptomatic). The IPSS score interpretation are symptom score less than equal to 7 (mild), symptom score range 8-19 (moderate) and symptom score range of 20-35 (severe) (Barry et al., 1995; Barry et al., 1992) . The patient's IPSS score was 7, with little impact on his overall quality of life. On further history taking using open ended questions and review of his 7 day urinary frequency and volume chart; he denied any bothersome lower urinary tract symptoms.
The main diagnostic tools in prostate cancer include a Digital Rectal Examination (DRE), serum concentration of PSA, and transrectal ultrasound guided biopsies, CT/MRI Pelvis scan and Bone scan (Heidenreich et al., 2014b; British Association of Urological Surgeons, 2013) . PSA is organ specific but it is not cancer specific because serum concentration of PSA can be elevated in the presence of prostatitis, benign prostatic hyperplasia (BPH) and other non-malignant conditions. Several modifications of serum PSA values have been described that may improve the specificity of PSA in the early detection of prostate cancer. The include, PSA density, PSA density of the transition zone, age-specific reference ranges and PSA molecular forms (Heidenreich et al., 2014b) .
In keeping with local clinical guidelines, PSA interpretation was based on regional population age stratified ranges for PSA levels (40-49 years <2·8 ug/L, 50-59 years <4.0 ug/L, 60-69 years <5·3 ug/L and 70-79 years <6·5 ug/L) (North of Scotland Cancer Network, 2010). The patient's PSA blood test was 456·9 ug/L significantly high for his 75 years. The specialist nurse took time and care to discuss his PSA result, along with GP' findings on DRE, lower back pain, to explain that these findings indicate a likely, clinical diagnosis of prostate cancer, but further investigations are needed to ensure a clear clinical picture, taking care to share 'bad news' (Baile et al., 2000) . The specialist nurse opted to repeat his full bloods to include (U&E's, LFT's, bone group, FBC and PSA) (North of Scotland Cancer Network, 2010) with the patient's agreement, as the GP only checked his PSA with no other biochemistry, and only one PSA reading to date.
The DRE is a fundamental component of the assessment of the prostate gland (Heidenreich et al., 2014b) . A PSA level does not preclude a diagnosis of prostate cancer. Therefore, with verbal consent the DRE was repeated as discrepancies have been found between General Practitioner's DRE findings and Urology Specialist Teams (Miñana López et al., 2014) . The DRE examination performed by the specialist nurse revealed a bilaterally firm, nodular at the apex, T3 examination. Together with the abnormal DRE and high PSA there was enough evidence to 'suspect' a clinical diagnosis of prostate cancer.
Given his history of back pain, the physical examination included consideration of spinal cord compression. Spinal cord compression occurs when metastases invade the epidural space or when the vertebral bodies cause compression of the spinal cord and its blood supply resulting in ischemia. The prevalence of spinal cord compression is around 5-9% of men affected by metastatic prostate cancer (Osborn et al., 1995) . Metastatic spinal cord compression is a clinical emergency, and it's clinical presentation must be recognized early. The patient experienced lower back pain, but did not experience any of the following signs or symptoms: narrow band of pain around the abdomen or chest, his pain did not move down his legs or arms, no lower limb weakness or unsteadiness on his feet, no paraesthesia, pins or needles, or numbness, and he had full control of his bladder and bowels (Levack et al., 2002 scale of 0 to 10 (no pain to worst imaginable pain) (McCormack et al., 1988) The patient rated his pain as a 3/4 (mild/moderate pain). The visual analogue scale has been shown to have good test-re-test reliability (Williamson and Hoggart, 2005) . The patient articulated that his pain was well controlled on his current analgesia plan of co-codamol as already prescribed by his GP, and completely resolved his pain.
As part of the 'problem solving' component of the consultation, an agreed clinical management plan was formulated in partnership with the patient, specialist nurse, and overall responsible Consultant. The management plan was 'documented' on the MDT form, and GP informed by electronic letter communication, which included the following next steps in care: Bone scan, await review of full bloods and MDT, as illustrated in Figure 2 . The underlying principles of record keeping for nurses are detailed in national guidelines for records and record keeping (Nursing and Midwifery Council, 2004) . Specifically, in relation to good record keeping for prescribing practice nurses should refer to the standards and proficiency of nurse prescribers (Nursing and Midwifery Council, 2006b) .
As part of 'safety netting' and 'clarification' a further appointment was given to discuss his results following MDT and any recommendations for treatment, or further investigations. The specialist nurse's contact details were provided to ensure a point of contact for any further information, advice or support in the interim period to his next appointment.
The MDT was held following the completion of the agreed management plan. The results confirmed cT3, Nx, M1b prostate cancer, see Table 2 for clinical summary.
During the MDT discussions there was some debate around whether the patient should be prescribed a Luteinising-hormone-releasing hormone agonists (LHRH) Agonists (Pituitary Down-Regulators), or LHRH antagonists, versus bilateral subcapsular orchidectomy (NICE, 2014 Midwifery Council (2007, 2006a) clearly distinguishes that prescribing should be evidence-based to safeguard patient safety at all times. As a consequence, prescribers should practice with evidence guidelines and frameworks 
TREATMENT
Testosterone is the male sex hormone and is essential for prostate cancer cell growth. In the context of metastatic prostate cancer, the aim of treatment is to reduce systemic testosterone levels or prevent testosterone binding to the androgen receptor. Castration slows the progression of prostate cancer, and can prolong life and palliate symptoms (NICE, 2014) . Castration can be achieved by surgical intervention with a bilateral subcapsular orchidectomy or by pharmacology interventions namely using LHRH agonists, LHRH antagonists or anti-androgens (NICE, 2014; Heidenreich et al., 2014a) .
LHRH AGONISTS (PITUITARY DOWN-REGULATORS)
The use of LHRH agonists is known as chemical or medical castration. An agonist is a chemical that mimics a naturally-occurring substance in the body and produces the same physiological effect. The agonist, therefore, will occupy cell receptors of the chemical it is mimicking. An agonist has a longer biological half-life, meaning the body takes longer to metabolize and eliminate the agonist. The agonist therefore will bind to a receptor for a longer period of time and mimics normal LHRH, and binds to the receptors of the pituitary gland that receive normal LHRH. LHRH analogues, such as leuprorelin, goserelin and triptorelin are potent LHRH agonists. For a period of 7-10 days, the pituitary gland perceives the LHRH agonist as normal LHRH and triggers the testicles to produce large amounts of testosterone. A sudden rise of testosterone is known as 'tumour-flare' in which the tumour can grow and cause clinical complications such as bone pain, spinal cord compression and ureteric obstruction (NICE, 2014; British Association of Urological Surgeons, 2013). After 7-21 days, the LHRH agonist still binds to the pituitary gland's receptors, whereas normal LHRH would have been metabolized. The pituitary gland stops triggering the testicles to produce testosterone.
Therefore, to prevent tumour-flare, an anti-androgen is given to the man for 1-2 weeks before initiating the LHRH agonist, after which a further two weeks of anti-androgen treatment is required. The three main LHRH agonists in use are Leuprorelin, Goserelin and Triptorelin. Leuprorelin and Goserelin are administered subcutaneously, whereas Triptorelin is administered intramuscularly. Another LHRH agonist drug is called Vantas ® (histrelin acetate). It is given once a year as an implant under the skin and approved for use in the NHS in Scotland by the Scottish Medicines Consortium (NHS Scotland, 2009 
LHRH ANTAGONISTS
LHRH antagonist, Degarelix (brand name Firmagon) cause rapid androgen depletion by immediate inhibition of LHRH receptors in the anterior pituitary gland. These peptides inhibit LHRH release without causing the initial stimulation by blocking the pituitary receptors and therefore, not associated with a surge in testosterone flare. With the use of this drug, the administration of anti-androgens is not required. The use of LHRH antagonists can be beneficial in patients with bony metastases or bladder neck obstruction where tumour control without testosterone surge is clinically important. Degarelix is administered monthly as a subcutaneous injection in the abdominal region.
ANTI-ANDROGENS
Androgens are hormones. Anti-androgens are taken as tablet form daily and do not alter the levels of circulating androgens. Anti-androgens are drugs that block the action of these hormones made by the testicles and/or adrenal glands. Prostate cancer cells rely on androgens for growth and to avoid apoptosis. There are two classifications of these drugs, steroidal anti-androgens and 'pure' anti-androgens (Joint Formulary Committee, 2016) . The steroidal anti-androgens include megestrol (Megace). The 'pure' or non-steroidal anti-androgens include Bicalutamide (Casodex), Flutamide (Chimas, Dronenil), and Cyproterone Acetate (Cyprostat). Anti-androgens can be added to LHRH agonist or antagonist therapy when men begin to relapse, this combination therapy is known as complete, total or maximum androgen blockade, this classification of drugs can be used as monotherapy (steroidal anti-androgens).
BILATERAL SUBCAPSULAR ORCHIDECTOMY
The surgical option, bilateral subcapsular orchidectomy is not widely performed in modern healthcare, yet clinical guidelines recommend that all men with metastatic prostate cancer are offered this procedure as an alternative to continuous luteinising hormone-releasing hormone agonist therapy (NICE, 2014) . Castration is achieved within 12 h, but bilateral subcapsular orchidectomy is irreversible and patients should be counselled. This is a relatively uncomplicated surgery, cost-effective intervention in the long-term, and can be performed under local anaesthetic. It is thought that the main limitation of this intervention is the psychological impact on men. Evidence suggests that psychological effects included changes in body image, emotional effects, including moodiness and short temper, crying with minimal provocation as well as feeling depressed and anxious (Kumar et al., 2005) , but noteworthy these side-effects are prevalent in men treated by medical castration.
CRITICALLY APPRAISE CURRENT ISSUES AND NON-MEDICAL FACTORS IMPACTING UPON AND INFLUENCING PRESCRIBING PRACTICE
Independent non-medical prescribers need to be aware of a range of contemporary clinical and non-clinical factors that might influence prescribing practice within the scope of prostate cancer care. Specific within the context of prescribing hormone therapy for this case study, the specialist urology team prescribe within the 'Urology Specialist Formulary List' informed by the Board Area Drug & Theraputic Committee (ADTC) (NHS Inform, 2016) . The included medications available on the Urology Specialist Formulary include the following drugs: Cyproterone Acetate, Triptoreline, Goserelin and Degarelix. There are no known pharmacodynamic or pharmacokinetic drug reactions with the patient's existing medication of Co-codamol (Joint Formulary Committee, 2016) . Moreover, from his most recent bloods he did not have any renal or liver impairment, as a further special consideration when prescribing hormone therapy (Joint Formulary Committee, 2016) . Within, the case study's specialist formulary Degarelix is prescribed if patients present with significant risk of ureteric obstruction and other signs of locally advanced and metastatic disease that need urgent treatment, such as risk of spinal cord compression (National Institute for Health and Care Excellence, 2014). The patient did not present with any of these risk factors, and therefore, Degarelix was not considered appropriate to prescribe within the context of MDT agreement.
Based upon the cost analysis of prescribing hormone therapy (see Table 3 ), the specialist nurse would consider to discuss with him the consideration of a bilateral orchiectomy in keeping with evidence-based guidelines (NICE, 2014) . This modality could demonstrate cost efficiency (Krahn et al., 2014) compared to prescribing LHRH injections indefinitely (that would avoid patients being administered injections every 3 or 6 months), but this treatment modality may require additional appropriate psychological care (Kumar et al., 2005) . Interestingly, a recent study identified that some men articulated that they would have preferred surgery, but this option was never discussed with them, and that they experienced changes in their anatomy with their testicles shrinking and almost disappearing on LHRH injections (Paterson et al., unpublished results) .
As an alternative, the non-medical prescriber would opt to prescribe Cyproterone Acetate tablets 100 mg twice daily for 28 days and Triptorelin 11·25 mg injection (Decapeptyl ® SR; Ipsen Valera Pharmaceuticals) (3 monthly preparation) to be given at the start of week 2 of taking anti-androgen tablets (Joint Formulary Committee, 2016) . Any adverse drug reaction (ADR) to these medications would be reported in the Yellow Card commission on human medicines published in the British National Formulary (BNF) (Joint Formulary Committee, 2016). The patient was advised of the potential side-effects and risks, and a supported self-management plan was developed in partnership to monitor response to medication and lifestyle advice to optimize quality of life (Paterson et al., 2014; Nursing and Midwifery Council, 2006a) . Other contextual factors that can influence our prescribing practice are clinical governing bodies such as, NICE. Recently, NICE have recommended that Degarelix should no longer be approved for use in patients presenting acute with metastatic prostate cancer (a group within its current licensed indication). This recommendation raises concerns for a number of Doctors, as this is the only drug of its class available. It is clear that NHS costs are an issue but when we consider Degaralix costs around £1500 a year, when many other approved cancer drugs cost far more per month such as, Abiaterone £2930 per month (Joint Formulary Committee, 2016) , arguably Degarelix does not seem that expensive for the benefit this drug can provide (immediate testosterone suppression; avoidance of testosterone flare; no need for anti-androgen).
Moreover, evidence identifies that men with prostate cancer on androgen deprivation therapy (ADT) carry a significant risk of cardiovascular disease (Keating et al., 2006) , undoubtedly increasing the risk of death. Importantly, emerging evidence suggests that for patients who had a significant history of cardiovascular disease at baseline and treated with Degaralix, demonstrated a significantly lower probability of a cardiovascular event or death compared to those treated with a LHRH agonist (Albertsen et al., 2014; Smith et al., 2011) . Thus, within the larger context of prescribing, it could be argued that GNRH antagonists could be a viewed as an alternative to GNRH agonists for men with pre-existing cardiovascular disease. Noteworthy, some caution is taken as this was a post-hoc analysis of pooled data, and a longer follow-up is needed to rigorously assess the long-term efficacy of GNRH antagonists versus GNRH agonists.
Despite the Review of Prescribing, Supply and Administration of Medicines and the introduction of non-medical prescribing (Department of Health, 1999) , several studies have identified that nurses are still not prescribing following successful attainment of their non-medical prescribing qualifications (While and Biggs, 2004; Larsen, 2004) . A recent mixed methods study identified a range of factors that can influence non-medical prescribing such as: lack of peer clinical supervision, inadequate knowledge of pharmacology, lack of diagnostic reasoning, limited formulary and variations in prescribing practices among individual Doctors, reticence to challenge treatments already initiated by another team member, fear of prescribing for patients with multiple co-morbidities, polypharmacy and information from pharmaceutical companies (Latter et al., 2010; While and Biggs, 2004) . Further research is needed to evaluate the nature and effects of these influences on prescribing decisions and practice within a variety of clinical contexts across both primary and secondary care. Little is known about the prescribing influences specifically in prostate cancer care, but it is suggested nurses in this field should keep in mind such factors and seek further support and professional development to optimize prescribing practice, if required. Other factors that can influences prescribing include patients desires and expectations of medications (While and Biggs, 2004) , important influences to optimize person-centred care, but can also be challenging. Non-medical prescribers not only need to be aware of the potential influences on prescribing practice but they also need to think critically about their role within the wider MDT.
REFLECT AND CRITICALLY EVALUATE THE PROSTATE CANCER SPECIALIST NURSE'S CONTRIBUTION TO THE MULTIDISCIPLINARY TEAM WITHIN A FRAMEWORK OF PROFESSIONAL ACCOUNTABILITY AND RESPONSIBILITY
It is recognized that the success of non-medical prescribing is dependent upon the contributions from a number of practitioners, including specialist nurses, pharmacists and doctors, and the wider prostate cancer MDT team and the ability of these professionals to work together as a robust and collective team. Within the clinical context of nurse-led prostate cancer clinic's, services, which include prostate assessment, performing prostate biopsies, insertion of fiducial gold seed markers in preparation of Intensity Modulated Radiotherapy Treatment, and Advanced Prostate Cancer Clinics for men with metastatic disease that prescribing practice is embedded (Prostate Cancer UK, 2014). Evidence acknowledges that men affected by prostate cancer can experience a host of unmet supportive care needs (Paterson et al., 2015c) , reduced quality of life (Paterson et al., 2013; Cockle-Hearne et al., 2013; Ream et al., 2008) , and evidence-based recommendation's enforce the need for MDT working (Paterson et al., 2015a) .
Each MDT member should have the pre-requisite knowledge of the basic sciences and clinical practice, and awareness of the expertise of other members. Together, MDT members should be capable of assessing and managing the medical, physical, psycho-social, vocational and social aspects of prostate cancer as a long-term condition (NICE, 2014) . Within the MDT team, a coordinated approach is crucial to facilitate ongoing and effective regular communication between all team members and consistent practice (British Association of Urological Surgeons, 2013) . This is vitally important as there have been concerns following the legislative changes that have enabled nurses to prescribe from the whole BNF (Stenner et al., 2011; Latter et al., 2010; Stenner et al., 2010) ' [25.p (Stenner et al., 2009)] .
Ultimately, all team members should work together to meet the needs of the individual patient. Not only is an effective MDT essential to safe prescribing practice, but collaborative working ensures prescribing is not performed in isolation. Moreover, within the prescribing context of prostate cancer specialist nurses, we work within set agreed Specialist Urology Formulary, that helps to protect professional accountability and promotes safe and responsible prescribing (NHS Inform, 2016) .
As the number of men living with and beyond prostate cancer continues to rise (Torre et al., 2015) existing models of nurse-led practice will continue to emerge. Therefore, medical and nursing leadership within local clinical directorates should acknowledge the unique contribution of nursing delivering an advanced level of practice, but support and facilitate robust audit, monitoring and evaluation of prescribing practice. It is also important that non-medical prescribing within the role of the specialist nurses have this role clearly identified in their job description/employment contracts to ensure appropriate indemnity cover, in addition to other professional representatives (Scottish Government, 2006) . We recommend that all novice non-medical prescribers have quality assurance systems in place for monitoring prescribing and individual practitioners regularly audit there practice, to promote continual professional development and critical reflection on their practice.
CONCLUSION
This paper set out to critically review evidence-based recommendations for non-medical prescribing in prostate cancer care using a case study reflection. There are a number of complexities and potential difficulties faced when extending professional roles, accountability and responsibilities required in contemporary healthcare. Non-medical prescribers must be committed to continual professional development, and prescribe safely within individual competencies and scopes of professional practice. There is a pressing need for further research to assess and evaluate prescribing practices within the context of prostate cancer care, with a particular focus on the nature of influencing factors on prescribing decisions, cost-effectiveness and a more detailed understanding of how team working and inter-team referral affects prescribing decisions between the MDT members.
IMPLICATIONS FOR PRACTICE AND/OR POLICY
Nurses need to demonstrate the value of non-medical prescribing in prostate cancer care and further service evaluation and research is needed in this clinical context.
WHAT IS KNOWN ABOUT THIS TOPIC
• Open formulary non-medical prescribing has been rapidly introduced over the past decade.
• Little research or evaluation has been conducted in prostate cancer care to date.
• National and International Cancer reforms recommended the introduction of nurse-led prostate cancer clinics.
WHAT THIS PAPER ADDS
• Non-medical prescribing (NMP) in prostate cancer is appropriate and well-established professional relationships are a key to success.
• NMP is not appropriate to be conducted in isolation of the multidisciplinary team (MDT).
